128 related articles for article (PubMed ID: 37752892)
21. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.
Motzer R; Porta C; Alekseev B; Rha SY; Choueiri TK; Mendez-Vidal MJ; Hong SH; Kapoor A; Goh JC; Eto M; Bennett L; Wang J; Pan JJ; Saretsky TL; Perini RF; He CS; Mody K; Cella D
Lancet Oncol; 2022 Jun; 23(6):768-780. PubMed ID: 35489363
[TBL] [Abstract][Full Text] [Related]
22. Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial.
McGregor B; O'Donnell PH; Balar A; Petrylak D; Rosenberg J; Yu EY; Quinn DI; Heath EI; Campbell M; Hepp Z; McKay C; Steinberg J; Regnault A; Mazerolle F; Galsky MD
Eur Urol; 2022 May; 81(5):515-522. PubMed ID: 35168844
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study.
Khattak MA; Luke JJ; Long GV; Ascierto PA; Rutkowski P; Schadendorf D; Robert C; Grob JJ; de la Cruz Merino L; Del Vecchio M; Spagnolo F; Mackiewicz J; Chiarion-Sileni V; Carlino MS; Mohr P; De Galitiis F; Ross MI; Eroglu Z; Chen K; Jiang R; Fukunaga-Kalabis M; Krepler C; Eggermont AMM; Kirkwood JM
Eur J Cancer; 2022 Nov; 176():207-217. PubMed ID: 36202690
[TBL] [Abstract][Full Text] [Related]
24. Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma.
Tam CS; Quach H; Nicol A; Badoux X; Rose H; Prince HM; Leahy MF; Eek R; Wickham N; Patil SS; Huang J; Prathikanti R; Cohen A; Elstrom R; Reed W; Schneider J; Flinn IW
Blood Adv; 2020 Oct; 4(19):4802-4811. PubMed ID: 33022066
[TBL] [Abstract][Full Text] [Related]
25. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.
Xu W; Yang S; Zhou K; Pan L; Li Z; Zhou J; Gao S; Zhou D; Hu J; Feng R; Huang H; Ji M; Guo H; Huang J; Novotny W; Feng S; Li J
J Hematol Oncol; 2020 May; 13(1):48. PubMed ID: 32393328
[TBL] [Abstract][Full Text] [Related]
26. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
Sharman JP; Brander DM; Mato AR; Ghosh N; Schuster SJ; Kambhampati S; Burke JM; Lansigan F; Schreeder MT; Lunin SD; Zweibach A; Shtivelband M; Travis PM; Chandler JC; Kolibaba KS; Sportelli P; Miskin HP; Weiss MS; Flinn IW
Lancet Haematol; 2021 Apr; 8(4):e254-e266. PubMed ID: 33631112
[TBL] [Abstract][Full Text] [Related]
27. Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial.
Cochrane T; Enrico A; Gomez-Almaguer D; Hadjiev E; Lech-Maranda E; Masszi T; Nikitin E; Robak T; Weinkove R; Wu SJ; Sail KR; Pesko J; Pai M; Komlosi V; Anderson MA
Leuk Lymphoma; 2022 Feb; 63(2):304-314. PubMed ID: 34632935
[TBL] [Abstract][Full Text] [Related]
28. Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE).
Necchi A; Nishiyama H; Matsubara N; Lee JL; Petrylak DP; de Wit R; Drakaki A; Liepa AM; Mao H; Bell-McGuinn K; Powles T
BMC Urol; 2020 Nov; 20(1):181. PubMed ID: 33160359
[TBL] [Abstract][Full Text] [Related]
29. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
[TBL] [Abstract][Full Text] [Related]
30. Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial.
Al-Sawaf O; Gentile B; Devine J; Zhang C; Sail K; Tandon M; Fink AM; Kutsch N; Wendtner CM; Eichhorst B; Hallek M; Fischer K
Am J Hematol; 2021 Sep; 96(9):1112-1119. PubMed ID: 34050972
[TBL] [Abstract][Full Text] [Related]
31. Improvements in Health-related Quality of Life and Symptoms in Patients With Previously Untreated Chronic Lymphocytic Leukemia: Final Results From the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine.
Danilov AV; Yimer HA; Boxer MA; Burke JM; Babu S; Li J; Mun Y; Trask PC; Masaquel AS; Sharman JP
Clin Lymphoma Myeloma Leuk; 2022 Feb; 22(2):121-128. PubMed ID: 34674981
[TBL] [Abstract][Full Text] [Related]
32. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.
Nastoupil LJ; Lunning MA; Vose JM; Schreeder MT; Siddiqi T; Flowers CR; Cohen JB; Burger JA; Wierda WG; O'Brien S; Sportelli P; Miskin HP; Purdom MA; Weiss MS; Fowler NH
Lancet Haematol; 2019 Feb; 6(2):e100-e109. PubMed ID: 30709431
[TBL] [Abstract][Full Text] [Related]
33. BTK Inhibitor Options Expand for CLL/SLL.
Cancer Discov; 2023 Feb; 13(2):252. PubMed ID: 36524825
[TBL] [Abstract][Full Text] [Related]
34. Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.
Petrella TM; Robert C; Richtig E; Miller WH; Masucci GV; Walpole E; Lebbe C; Steven N; Middleton MR; Hille D; Zhou W; Ibrahim N; Cebon J
Eur J Cancer; 2017 Nov; 86():115-124. PubMed ID: 28987768
[TBL] [Abstract][Full Text] [Related]
35. Ibrutinib in Advanced Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Lower Risk of Hepatitis B Virus Reactivation.
Yang S; Zhu R; Li N; Feng Y; Zuo R; Gale RP; Huang X
Acta Haematol; 2022; 145(1):54-62. PubMed ID: 34569486
[TBL] [Abstract][Full Text] [Related]
36. Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.
Twelves C; Cortés J; O'Shaughnessy J; Awada A; Perez EA; Im SA; Gómez-Pardo P; Schwartzberg LS; Diéras V; Yardley DA; Potter DA; Mailliez A; Moreno-Aspitia A; Ahn JS; Zhao C; Hoch U; Tagliaferri M; Hannah AL; Rugo HS
Eur J Cancer; 2017 May; 76():205-215. PubMed ID: 28360015
[TBL] [Abstract][Full Text] [Related]
37. [Translated article] Adjusted indirect comparison of zanubrutinib and ibrutinib in first-line treatment of chronic lymphocytic leukemia.
Salmerón-Navas FJ; Barreiro-Fernández EM; Fénix-Caballero S
Farm Hosp; 2024; 48(1):T9-T15. PubMed ID: 37845105
[TBL] [Abstract][Full Text] [Related]
38. Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial.
Soumerai JD; Mato AR; Dogan A; Seshan VE; Joffe E; Flaherty K; Carter J; Hochberg E; Barnes JA; Hamilton AM; Abramson JS; Batlevi CL; Matasar MJ; Noy A; Owens CN; Palomba ML; Kumar A; Takvorian T; Ni A; Choma M; Friedman C; Chadha P; Simkins E; Ruiters J; Sechio S; Portman D; Ramos L; Nolet N; Mahajan N; Martignetti R; Mi J; Scorsune K; Lynch J; McGree B; Hughes S; Grieve C; Roeker LE; Thompson M; Johnson PC; Roshal M; Huang J; Biondo J; Wu Q; Jacob A; Abdel-Wahab O; Zelenetz AD
Lancet Haematol; 2021 Dec; 8(12):e879-e890. PubMed ID: 34826411
[TBL] [Abstract][Full Text] [Related]
39. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
40. Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option.
Molica S; Tam C; Allsup D; Polliack A
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
